Marvel Biosciences Corp. News Releases

Marvel Biosciences Announces Closing of Convertible Debenture Offering

Fri, 17 Apr 2026 16:30:00 -0400

Calgary, Alberta--(Newsfile Corp. - April 17, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) ("Marvel" or the "Company") announced today that it has completed the closing of the previously announced non-brokered private placement of unsecured convertible debentures ("Debentures") for gross proceeds of $500,000 (the "Offering"), subject to final approval of the TSX Venture Exchange.The Debentures bear interest at the rate of twelve percent (12%) per annum, payable annually and mature on December...

Marvel Biosciences Announces an Amendment to the Conversion Price for Marvel's Proposed Convertible Debenture Offering

Mon, 13 Apr 2026 17:31:00 -0400

Calgary, Alberta--(Newsfile Corp. - April 13, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) ("Marvel" or the "Company") Further to the Company's press release of April 8, 2026, announcing its intention to complete a non-brokered private placement offering of unsecured convertible debentures ("Debentures") in the principal amount of up to $500,000 (the "Offering"), Marvel wishes to announce that it has amended the conversation price for the Debentures, which are convertible at the holder's option...

Marvel Biosciences Announces Proposed Convertible Debenture Offering

Wed, 08 Apr 2026 16:30:00 -0400

Calgary, Alberta--(Newsfile Corp. - April 8, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) ("Marvel" or the "Company") announced today its intention to complete a non-brokered private placement offering of unsecured convertible debentures ("Debentures") in the principal amount of up to $500,000 (the "Offering"), subject to final approval of the TSX Venture Exchange.The Debentures will bear interest at the rate of twelve percent (12%) per annum, payable annually and mature on December 31, 2027....

Marvel Biosciences Receives Notice of Allowance for US Patent Application Covering Composition of Matter for Its Lead Therapeutic Candidate MB-204

Wed, 18 Mar 2026 07:00:00 -0400

Calgary, Alberta--(Newsfile Corp. - March 18, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "Company"), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, is pleased to announce that the US Patent Office has issued Patent No. 12,570,656 B2 for MB-204 granting broad composition of matter and methods of use claims titled "Purine Compounds...

Marvel Biosciences Sponsors Scientific Meeting on Purines

Wed, 04 Mar 2026 07:00:00 -0500

Calgary, Alberta--(Newsfile Corp. - March 4, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "Company"), a biotechnology company developing novel therapies for neurological and neurodevelopmental disorders, today announced it is sponsoring the 3rd European Purine Meeting taking place in Bordeaux, France, from June 30 to July 3, 2026.The 3rd European Purine meeting will bring together worldwide...

Marvel Biosciences Announces Grant of Deferred Share Units

Wed, 18 Feb 2026 16:30:00 -0500

Calgary, Alberta--(Newsfile Corp. - February 18, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces the award of 50,001 deferred share units ("DSUs") to Marvel's three independent directors, in lieu of cash payment for directors' fees.The DSUs will all vest on February 17, 2027. Vested DSUs shall be settled upon the directors' separation from service from the Company and expire 365 days...

Marvel Biosciences Secures Funding to Develop Child-Friendly Liquid Formulation for Neurodevelopmental Disorders

Wed, 18 Feb 2026 08:00:00 -0500

Calgary, Alberta--(Newsfile Corp. - February 18, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), is pleased to announce that it is receiving advisory services and funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support research and development of a pediatric-friendly liquid formulation of its lead compound, MB-204.The NRC IRAP-supported project will focus on creating a small-volume oral liquid formulation designed for...

Marvel Biosciences Receives Japanese Patent Covering Composition of Matter for Its Lead Therapeutic Candidate MB-204

Tue, 03 Feb 2026 16:30:00 -0500

Calgary, Alberta--(Newsfile Corp. - February 3, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "Company"), a drug discovery company developing novel therapeutics for autism spectrum disorder and related neurological conditions, is pleased to announce that the Japan Patent Office has granted Japanese Patent No. 2022-554855, titled "Purine Compounds for Treating Disorders," covering composition...

Marvel Biosciences Announces Grant of Deferred Share Units

Mon, 10 Nov 2025 17:15:00 -0500

Calgary, Alberta--(Newsfile Corp. - November 10, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces the award of 35,697 deferred share units ("DSUs") to Marvel's three independent directors, in lieu of cash payment for directors' fees.The DSUs will all vest on October 31, 2026. Vested DSUs shall be settled upon the directors' separation from service from the Company and expire 365 days...

Marvel Biosciences Announces Acceleration of Warrant Expiry Date

Fri, 03 Oct 2025 05:00:00 -0400

Calgary, Alberta--(Newsfile Corp. - October 3, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is announcing that, further to the Company's press releases of May 16, 2024, June 21, 2024 and July 19, 2024, the Company is formally providing notice that it will be accelerating the expiry date of the warrants issued in relation to its non-brokered private placement unit offering (the "Offering"). The...